Pomalidomide 4'-alkylC5-acid is primarily used in the development of novel therapeutic agents, particularly in the field of oncology. Its application is focused on enhancing the efficacy of immunomodulatory drugs, especially in the treatment of multiple myeloma and other hematologic malignancies. The compound is designed to improve drug delivery and targeting, potentially reducing side effects and increasing patient tolerance. It is also being investigated for its role in modulating the immune system to better recognize and destroy cancer cells. Additionally, its structural modifications may contribute to overcoming drug resistance, a significant challenge in cancer therapy. Research is ongoing to explore its potential in combination therapies and its broader applicability in treating various cancers.